{"brief_title": "A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g", "brief_summary": "This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.", "condition": "Psoriasis", "intervention_type": "Drug", "intervention_name": "Raptiva (efalizumab)", "criteria": "Inclusion Criteria: - Signed informed consent - Previous participation in Study ACD2600g - For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study Exclusion Criteria: - Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00096603.xml"}